GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (XPAR:IVA) » Definitions » Additional Paid-In Capital

Inventiva (XPAR:IVA) Additional Paid-In Capital : €201.86 Mil(As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Inventiva Additional Paid-In Capital?


Inventiva's quarterly additional paid-in capital increased from Jun. 2023 (€173.89 Mil) to Dec. 2023 (€201.86 Mil) but then stayed the same from Dec. 2023 (€201.86 Mil) to Jun. 2024 (€201.86 Mil).

Inventiva's annual additional paid-in capital increased from Dec. 2021 (€165.07 Mil) to Dec. 2022 (€173.89 Mil) and increased from Dec. 2022 (€173.89 Mil) to Dec. 2023 (€201.86 Mil).

Inventiva Additional Paid-In Capital Historical Data

The historical data trend for Inventiva's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inventiva Additional Paid-In Capital Chart

Inventiva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 86.01 139.67 165.07 173.89 201.86

Inventiva Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 173.89 173.89 173.89 201.86 201.86

Inventiva Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Inventiva Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Inventiva's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Inventiva Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (XPAR:IVA) » Definitions » Additional Paid-In Capital
Comparable Companies
XPAR:MAAT XPAR:TNG XPAR:ADOC XPAR:NANO XPAR:ALCLS XPAR:OSE XPAR:IPH XPAR:DBV XPAR:GNFT XPAR:ABNX VRTX ASX:CSL REGN XKRX:207940 XBRU:UCB XBRU:ARGX ALNY BNTX XKRX:068270 BGNE
Traded in Other Exchanges
IVA:USA 0RNK:UK 6IV:Germany
Address
50 rue de Dijon, Daix, FRA, 21121
Website
https://www.inventivapharma.com
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.